Under the Agreement, Valeo will be responsible for medical and commercial activities for an initial 8 year period.
How Significant Is This Market?
At present, almost 4 million Canadians are living with asthma a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies. The Canadian market for asthma medication exceeds $700M annually.
What Does The CEO of Valeo say about the deal?
“We are extremely pleased to be partnering with Novartis to launch these two asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”
Sit Back, relax and watch this powerful interview with Steve Saviuk , CEO of Valeo.
Posted by AGORACOM-JC
at 4:14 PM on Monday, March 29th, 2021
If you think about balloons / blimps when thinking about Helium uses, we wouldn’t blame you … but you’d also be missing out on a much much bigger picture.
Looking beyond just balloons, Helium is a high tech gas, with many uses in rocket engines, semiconductors, electronics, and health care. These sectors pressure the demand for helium in concert, making it a gas in very short supply. Prices have been rising due to a shortage in supply.
Saskatchewan is one of the only places on earth with current and past production of primary Helium. This is where Royal Helium comes into play as they are one of the largest land holders searching for Helium and have already drilled 3 holes at their Climax project.
Worldwide usable Helium is in short supply as demand is increasing, making it a high-priced commodity, take a seat and discover why Royal Helium is the next SmallCap Stock to discover.
Posted by AGORACOM-JC
at 10:47 AM on Monday, March 29th, 2021
Valeo to commercialize Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , 2 innovative asthma therapies approved by Health Canada
Positions Valeo as one of the leading Canadian Respiratory companies
Almost 4 million Canadians afflicted with asthma 1 ; Canadian market for asthma medication exceeds $700M annually 2
MONTREAL , March 29, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has entered into a Commercialization and Supply Agreement (the ” Agreement “) with Novartis Pharmaceuticals Canada Inc. (” Novartis “) for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate) 4 .
Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® for an initial 8 year period.
At present, almost 4 million Canadians are living with asthma 1 , a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies . Asthma related exacerbations are concerning because of their associated mortality burden and also because of the increased risk of side effects from the use of systemic corticosteroids. Furthermore, there is growing evidence highlighting the lack of symptom control currently achieved in asthma. 39% 5 of patients remain uncontrolled, despite available dual LABA/ICS medications, primarily due to low adherence, treatment misuse and poor inhaler technique. There is an urgent need to add effective maintenance treatment options to more efficiently address symptoms as well as asthma related long-term complications and mortality.
“We are extremely pleased to be partnering with Novartis to launch these two asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”
“This agreement with Valeo Pharma fits with our overall strategy to provide innovative medicines that have the potential to improve health outcomes,” said Andrea Marazzi , Head, Country Pharma Organization, Novartis Pharmaceuticals Canada Inc. “Valeo’s commitment and focus to bring Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® to Canadians, combined with our strong respiratory experience, brings a solution that will help make asthma control a more attainable goal for some Canadians.”
Commenting on this commercial agreement with Novartis, Frederic Fasano , Valeo’s recently appointed President and COO said, “Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® are both benefitting from an extensive phase III clinical trial program including more than 7,500 asthma patients. The efficacy of both treatments on symptoms, lung function and rate of exacerbations have been demonstrated and this will provide Canadian patients with a significant improvement over current standards of care.” He added, “This significant addition to our expanding product portfolio is key to achieving our growth objectives. It will provide the basis for the upscaling of our organization and set the stage for future international expansion.”
The Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will both be available in the hydrofluoroalkane/chlorofluorocarbon (HFA/CFC)-free Breezhaler ® device.
Atectura, Enerzair and Breezhaler are registered trademarks.
Posted by AGORACOM
at 10:14 AM on Monday, March 29th, 2021
TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), a leader in providing AI-powered healthcare solutions is pleased to announce that it has appointed Kingswood Capital Markets (“Kingswood”) in preparation to become a NASDAQ-listed company.
The acceptance of the application to list the Company’s common shares on NASDAQ will be subject to a number of regulatory and listing requirements, including without limitation: retaining the required number of market makers for the Company’s common shares; the filing of the applicable registration statement with the U.S. Securities and Exchange Commission to become a reporting company under the U.S. Securities Act; and the review of the Company and acceptance for listing by NASDAQ. There can be no assurance that NASDAQ acceptance will be granted should the Company submit its listing application.
Kingswood Capital Markets is a global full-service middle market investment bank. Kingswood helps its clients grow through optimal capital raising structures. Its team of experienced investment professionals has collectively financed over $50 billion in public and private capital markets and provides strategic solutions to clients across a wide spectrum of industries.
Kingswood’s expertise has been engaged to aid in both Predictmedix’s NASDAQ uplist and business growth, as part of the Company’s endeavors to disrupt the current healthcare and technology market in a safe, non-invasive, and economically sustainable way.
Posted by AGORACOM
at 10:01 AM on Monday, March 29th, 2021
VANCOUVER, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that its portfolio company Fantasy 360 Technologies Inc. d/b/a Immersive Tech (“Immersive”) has launched a non-brokered private placement of up to 4,285,714 subscription receipts of Immersive (“Subscription Receipts”) at a price of CAD$0.35 per Subscription Receipt for aggregate gross proceeds of up to CAD$1,500,000 (the “SR Offering”).
The Subscription Receipts will be issued pursuant to and governed by a subscription receipt agreement to be entered between Immersive and an escrow agent to be appointed by Immersive on or prior to the closing date of the SR Offering (the “SR Agreement”). The proceeds of the SR Offering, minus 10% which will be immediately released to Immersive on closing of the SR Offering for the purposes of satisfying the Escrow Release Conditions (as defined below) and for working capital and general corporate purposes, will be deposited in escrow pursuant to the SR Agreement.
In accordance with the SR Agreement, each Subscription Receipt shall be automatically converted without any further action on the part of the holder thereof into one unit of Immersive (each, a “SR Unit”) upon the satisfaction of certain escrow release conditions (the “Escrow Release Conditions”) including the receipt of conditional approval by Immersive with respect to the listing of the common shares of Immersive (“Immersive Shares”) on the Canadian Securities Exchange (the “CSE”) and the receipt of a final prospectus of Immersive in the Province of British Columbia. If the Escrow Release Conditions are not satisfied by August 31, 2021, the proceeds of the SR Offering will be returned to the subscribers.
Each SR Unit will consist of one Immersive Share and one-half of one Immersive Share purchase warrant (each whole warrant, an “SR Warrant”). Each SR Warrant will entitle the holder thereof to purchase one additional Immersive Share at a price of CAD$0.52 for a period of 24 months following the completion of a going-public transaction by Immersive.
Posted by AGORACOM
at 9:15 AM on Monday, March 29th, 2021
*19MM common share purchase warrants listed for trading on TSXV *Enlists AGORACOM for online outreach + marketing
TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that the TSX Venture Exchange (the “TSXV”) has accepted for listing 19,046,875 common share purchase warrants of the Company (the “Warrants”) issued in connection with the Company’s previously announced bought deal short-form prospectus offering of units. The TSXV has advised that these Warrants will be listed for trading on the TSXV under the symbol “WMD.WT” effective at market open on March 30, 2021.
Each Warrant entitles the holder thereof to purchase one common share of the Company (a “Common Share”) at an exercise price of $0.60 per Common Share until March 12, 2023. If after March 12, 2022 the daily volume-weighted average trading price of the Common Shares on the TSXV is equal to or greater than $0.96 per Common Share for the preceding 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the Warrants to a date that is 30 trading days following the date of the Company issues a press release disclosing such acceleration.
The Warrants are governed by a warrant indenture between the Company and TSX Trust Company dated March 12, 2021, a copy of which is available under the Company’s profile at www.sedar.com.
Digital Marketing & Awareness Service Agreement
WeedMD also announced today that it has engaged Agora Internet Relations Corp. (“AGORA“), a digital media marketing company that provides online outreach services (such as advertising, marketing and branding) to small and mid-cap public companies, effective as of March 18, 2021 (the “Service Agreement”) for an initial term of one year. The Company expects to receive significant exposure through millions of content brand insertions and extensive search engine marketing on the AGORACOM network over the period. Pursuant to the Service Agreement, WeedMD intends to issue shares to AGORA in exchange for the online services. The Company will pay a total fee of C$100,000 + HST by way of common shares (“Shares for Services”) of the Company, in incremental payments as follows:
$20,000 + HST Shares for Services due upon commencement effective March 18, 2021 for initial set up of HUB, marketing materials and search engine programs;
$20,000 + HST Shares for Services at end of third month June 18, 2021;
$20,000 + HST Shares for Services at end of sixth month September 18, 2021;
$20,000 + HST Shares for Services at end of ninth month December 18, 2021; and
$20,000 + HST Shares for Services at end of term March 31, 2022.
Per TSX Venture Policy 4.3 (Section 6.1), the deemed price of the securities to be issued will be determined after the date the services are provided to WeedMD in each period and be based upon the undiscounted market price of the Company’s common shares at the relevant time.
The agreement and issuance of shares is subject to the approval of the TSX Venture Exchange.
AGORACOM is the pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 7.7 million investors that visited 55.2 million times and read over 600 million pages of information over the last 10 years. The average visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry.
The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
This press release does not constitute an offer to sell or a solicitation of any offer to buy the securities in the United States, in any province or territory of Canada or in any other jurisdiction. There shall be no sale of the securities in any jurisdiction in which an offer to sell, a solicitation of an offer to buy or sale would be unlawful.
